Skip to Main Content

Paper Details

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage <i>RET</i> fusion-positive non-small cell lung cancer.
Front Oncol
2
2023
NSCLC, RET, early-stage, fusion, fusion-positive NSCLC, fusion-positive non-small cell lung cancer, patient, reactive pneumocyte proliferation, rearrangement during transfection, selpercatinib
Author NameAffiliation
Jonathan W GoldmanDavid Geffen School of Medicine, University of California los angeles
Jonathan W GoldmanDavid Geffen School of Medicine, University of California los angeles
Michael C FishbeinDavid Geffen School of Medicine, University of California los angeles
Alexander DrilonMemorial Sloan-Kettering Cancer Center New York
Alexander DrilonWeill Cornell Medical College
  • 1 - 5

Datasets

Release 1.2